Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Mai 2018 07:30 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Offering of Common Stock and Warrants

SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...
10. Mai 2018 16:05 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
21. März 2018 08:00 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN...
19. März 2018 07:30 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to...
08. März 2018 08:00 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two...
01. März 2018 16:05 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Announces Appointment of Chrysa Mineo as Independent Director

SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the...
27. Februar 2018 16:32 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
29. Januar 2018 08:00 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting

SAN DIEGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data...
04. Januar 2018 08:00 ET | Quelle: Cidara Therapeutics, Inc.

Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new...
28. November 2017 08:30 ET | Quelle: Cidara Therapeutics, Inc.

Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections

SAN DIEGO, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the...

Vorherige Seite